Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 5/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589447 | 1.00 | MEN1 (0.65) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| SCHEMBL23323077 | 1.00 | MEN1 (0.65) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| SCHEMBL19689047 | 0.95 | MEN1 (0.59) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| SCHEMBL31648586 | 0.85 | MEN1 (0.60) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| SCHEMBL31648821 | 0.85 | MEN1 (0.60) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| SCHEMBL22720995 | 0.85 | MEN1 (0.60) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| Hydrochloric Acid SCHEMBL31648191 | 0.84 | MEN1 (0.58) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| Hydrochloric Acid SCHEMBL31648321 | 0.83 | KMT2A (0.57) | MEN1KMT2AHTR2CTACR1CHRNB4 | |
| SCHEMBL23064531 | 0.82 | MEN1 (0.49) | MEN1KMT2AHTR2CCHRNB4CHRNA3 | |
| SCHEMBL28500167 | 0.82 | MEN1 (0.49) | MEN1KMT2AHTR2CCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110036009-A | Substituted pyrrolidines and their use in the treatment of cystic fibrosis | 艾伯维公司 | 2019-07-19 | — | — | CN | claimed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | claimed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-115490708-A | Sulfonamide macrocyclic derivatives, and preparation method and application thereof | 苏州亚盛药业有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| EP-1891038-B1 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | MEN1 3803/4885KMT2A 2464/4885HTR2C 3764/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | MEN1 3803/4885KMT2A 2464/4885HTR2C 3764/4885 |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | AR, FSHR, SHBG | MEN1 3899/4885KMT2A 3305/4885HTR2C 763/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | MEN1 3803/4885KMT2A 2464/4885HTR2C 3764/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | MEN1 4729/4885KMT2A 1920/4885HTR2C 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.